Mesenchymal stem cell therapy for cartilage repair - Medipost

Drug Profile

Mesenchymal stem cell therapy for cartilage repair - Medipost

Alternative Names: Cartistem

Latest Information Update: 18 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medipost
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Osteoarthritis
  • Phase III Knee injuries

Most Recent Events

  • 09 Apr 2015 The product i sitll in phase-III develoment for Knee injuries in South Korea and phase-I/II development for Osteoarthritis in USA
  • 25 Jun 2013 Medipost establishes Medipost Hong Kong to advance its mesenchymal stem cell therapy product in Asian markets
  • 19 Feb 2013 Medipost and Cell Therapies agree to co-market Mesenchymal stem cell therapy (Cartistem®) in Australia and New Zealand for Osteoarthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top